FBIO

Fortress Biotech, Inc. (FBIO) | Rumor.io

Fortress Biotech

FBIO

Attention (50-day avg)0%

Attention rank (50-day avg)#2,955

Bullish sentiment (50-day avg)79%

Price to earnings ratio0.82

Market capitalization72.4M

Earnings per share2.77

Dividend yield (TTM)—

Revenue (annual)63.3M

Net income (annual)-32.9M

Social

What share of all stock conversation is about FBIO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% 0

Sep 24

Fortress Biotech, Inc. (FBIO) may be heading for bankruptcy, according to a social media post.
The company's stock price has been volatile, with some users predicting a hard reversal and others holding firm at $5.
There is a disagreement among users about the terms of the license agreement between Alexion and Fortress, with some arguing that the approval milestone is tied to the FDA and others claiming that it is tied to the Japanese regulatory agency.

Generated by AI

Sentiment

Of the messages about FBIO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	100% +31.11	73.36% -9.22
Bearish	—	0%	0% -31.11	26.64% +9.22

Bullish· Feb 23

The company's debt will be completely cleared, allowing for the initiation of a Phase 1 study for a gene therapy that may effectively cure Menkes Disease.
The company's price-to-book value is undervalued, with a potential value in the double digits, comparable to similar companies in the industry.
The company is expected to be profitable this year, with a cash value of over $6 per share, and may see a significant increase in value once gene therapy trial data is released.

Bearish· Apr 1

The stock's low liquidity makes it vulnerable to short selling and price manipulation.
The company's recent positive earnings report and strong cash position do not seem to be reflected in the stock price, which is currently trading at around $2.47.
The stock's current price may be artificially low due to short selling and the anticipation of a potential dilution event, such as the conversion of preferred shares into common shares.

Generated by AI

Topics

Of the messages about FBIO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	59.99%
Technical Analysis	—	0%	0%	15.95%
Earnings	—	0%	0%	1.41%
Macro	—	0%	0%	13.13%
Analysts	—	0%	0%	8.68%
Controversies	—	0%	0%	0.85%

Earnings· Nov 9

Fortress Biotech reported Q3 2017 financial results and corporate highlights, including $FBIO.
Fortress Biotech missed EPS loss estimates by $0.24 and revenue expectations.
$FBIO missed EPS loss estimates by $0.24 and revenue expectations.

Announcements· Feb 23

Fortress Biotech's subsidiary Cyprium Therapeutics has sold its Rare Pediatric Disease Priority Review Voucher for $205 million.
The sale is related to the FDA approval of Zycubo for Menkes disease, and Cyprium is eligible for up to $129 million in milestones and ongoing tiered royalties on net sales of ZYCUBO.
Fortress Biotech's stock price has increased following the announcement, with some analysts expecting the company's value to increase significantly due to this news.

Generated by AI

Community

Of the messages about FBIO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	41.67%	29.17%	38.29%
Newcomers	—	58.33%	70.83%	61.71%

Regulars· Aug 3

The price of $FBIO may touch 60 and come closer to 120 in the next 2-3 weeks, and the stock may be range-bound between 2.90-3.10.
The stock has been experiencing a decline, with some users suggesting it may dip to the mid 2's again, while others believe it will recover to $3.10 in the next couple of days.
The company has a history of neglecting shareholders through dilution and manipulation, and some users are considering moving their money to a different biotech company with a better future.

Newcomers· Feb 23

Fortress Biotech's subsidiary Cyprium Therapeutics sold a Rare Pediatric Disease Priority Review Voucher for $205 million, increasing the company's market value.
The sale of the PRV will allow Cyprium to advance a gene therapy clinical trial for Menkes disease, which could generate significant revenue through high patient fees and royalties.
The deal could increase the value of Fortress Biotech's 74% stake in Cyprium, making it a more valuable asset for the company.

Generated by AI

MIAMI, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty income, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 28th Annual Global Investment Conference. The prese

22d agoca.finance.yahoo.com

Fortress Biotech, Inc. Q2 2026 Earnings Call Summary

Moby summary of Fortress Biotech, Inc.'s Q2 2026 earnings call

1mo agoYahoo Finance

Fortress Biotech earnings beat by $0.11, revenue fell short of estimates

1mo agoInvesting.com

Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Total net revenue increased 14% to $18.7 million for second quarter of 2026 compared to second quarter of 2025 Partnered programs continue to advance with Crystalys Therapeutics announcing its $130 million Series B financing to support the late-stage global development and commercialization preparation for dotinurad, and royalties generated from the launches of ZYCUBO® and UNLOXCYT™ MIAMI, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biophar

1mo agoYahoo Finance UK

Fortress Biotech: Q2 Earnings Snapshot

1mo agoBarchart.com

Fortress Biotech Q2 Earnings Call Highlights

Journey Medical reported higher second-quarter revenue and improved profitability, driven by continued prescription growth and improving payer reimbursement for its rosacea treatment Emrosi. Chief Executive Officer Claude Maraoui said the company generated positive EBITDA in the second quarter and

1mo agoYahoo Finance

Also Discussed

Investors talking about FBIO also mention

#	Name	Attention
1	Fortress Biotech Inc. Preferred Stock 9.375% PerpetualFBIOP	0%0
2	Journey Medical Corp. Common StockDERM	0%0
3	CKPT - Checkpoint Therapeutics, Inc.	——
4	Avenue Therapeutics Inc.ATXI	0%new
5	Mustang Bio Inc.MBIO	0%0
6	Replimune Group, Inc.REPL	0%0
7	Crinetics Pharmaceuticals IncCRNX	0%new
8	Grace Therapeutics, Inc.GRCE	0%new
9	Nuvation Bio Inc.NUVB	0%0
10	Sol-Gel Technologies Ltd.SLGL	0%0

Fortress Biotech, Inc.

Healthcare
Biotechnology

Fortress Biotech, Inc. is a biopharmaceutical company focused on developing, manufacturing, and commercializing pharmaceutical and biotechnology products. Fortress Biotech operates through two core areas: dermatology product sales and pharmaceutical and biotechnology product development. Its commercial portfolio includes prescription and specialty dermatology therapies used for conditions such as acne, rosacea, hyperhidrosis, and other skin-related disorders, alongside wound-care and supportive treatment products. The company also advances a broader pipeline and portfolio of assets through its subsidiary and partner network, supporting programs in areas such as rare diseases and oncology. Fortress Biotech plays a role in the healthcare market by combining product sales with asset development, royalties, and other collaboration-based revenue streams. Headquartered in Bay Harbor Islands, Florida, Fortress Biotech serves a range of medical professionals and patients across the United States and international markets.

Website

Location

1111 Kane Concourse

Bay Harbor Islands, FL, 33154

United States

Social

What share of all stock conversation is about FBIO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% 0

Sep 24

Fortress Biotech, Inc. (FBIO) may be heading for bankruptcy, according to a social media post.
The company's stock price has been volatile, with some users predicting a hard reversal and others holding firm at $5.
There is a disagreement among users about the terms of the license agreement between Alexion and Fortress, with some arguing that the approval milestone is tied to the FDA and others claiming that it is tied to the Japanese regulatory agency.

Generated by AI

Sentiment

Of the messages about FBIO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	100% +31.11	73.36% -9.22
Bearish	—	0%	0% -31.11	26.64% +9.22

Bullish· Feb 23

The company's debt will be completely cleared, allowing for the initiation of a Phase 1 study for a gene therapy that may effectively cure Menkes Disease.
The company's price-to-book value is undervalued, with a potential value in the double digits, comparable to similar companies in the industry.
The company is expected to be profitable this year, with a cash value of over $6 per share, and may see a significant increase in value once gene therapy trial data is released.

Bearish· Apr 1

The stock's low liquidity makes it vulnerable to short selling and price manipulation.
The company's recent positive earnings report and strong cash position do not seem to be reflected in the stock price, which is currently trading at around $2.47.
The stock's current price may be artificially low due to short selling and the anticipation of a potential dilution event, such as the conversion of preferred shares into common shares.

Generated by AI

Topics

Of the messages about FBIO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	59.99%
Technical Analysis	—	0%	0%	15.95%
Earnings	—	0%	0%	1.41%
Macro	—	0%	0%	13.13%
Analysts	—	0%	0%	8.68%
Controversies	—	0%	0%	0.85%

Earnings· Nov 9

Fortress Biotech reported Q3 2017 financial results and corporate highlights, including $FBIO.
Fortress Biotech missed EPS loss estimates by $0.24 and revenue expectations.
$FBIO missed EPS loss estimates by $0.24 and revenue expectations.

Announcements· Feb 23

Fortress Biotech's subsidiary Cyprium Therapeutics has sold its Rare Pediatric Disease Priority Review Voucher for $205 million.
The sale is related to the FDA approval of Zycubo for Menkes disease, and Cyprium is eligible for up to $129 million in milestones and ongoing tiered royalties on net sales of ZYCUBO.
Fortress Biotech's stock price has increased following the announcement, with some analysts expecting the company's value to increase significantly due to this news.

Generated by AI

Community

Of the messages about FBIO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	41.67%	29.17%	38.29%
Newcomers	—	58.33%	70.83%	61.71%

Regulars· Aug 3

The price of $FBIO may touch 60 and come closer to 120 in the next 2-3 weeks, and the stock may be range-bound between 2.90-3.10.
The stock has been experiencing a decline, with some users suggesting it may dip to the mid 2's again, while others believe it will recover to $3.10 in the next couple of days.
The company has a history of neglecting shareholders through dilution and manipulation, and some users are considering moving their money to a different biotech company with a better future.

Newcomers· Feb 23

Fortress Biotech's subsidiary Cyprium Therapeutics sold a Rare Pediatric Disease Priority Review Voucher for $205 million, increasing the company's market value.
The sale of the PRV will allow Cyprium to advance a gene therapy clinical trial for Menkes disease, which could generate significant revenue through high patient fees and royalties.
The deal could increase the value of Fortress Biotech's 74% stake in Cyprium, making it a more valuable asset for the company.

Generated by AI

Fortress Biotech

Social

Sep 24

Bullish· Feb 23

Bearish· Apr 1

Earnings· Nov 9

Announcements· Feb 23

Regulars· Aug 3

Newcomers· Feb 23

Fortress Biotech to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Fortress Biotech, Inc. Q2 2026 Earnings Call Summary

Fortress Biotech earnings beat by $0.11, revenue fell short of estimates

Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Fortress Biotech: Q2 Earnings Snapshot

Fortress Biotech Q2 Earnings Call Highlights

Also Discussed

Fortress Biotech, Inc.

Company Information

Location

Fortress Biotech to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Fortress Biotech, Inc. Q2 2026 Earnings Call Summary

Fortress Biotech earnings beat by $0.11, revenue fell short of estimates

Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Fortress Biotech: Q2 Earnings Snapshot

Fortress Biotech Q2 Earnings Call Highlights

Also Discussed

Social

Sep 24

Bullish· Feb 23

Bearish· Apr 1

Earnings· Nov 9

Announcements· Feb 23

Regulars· Aug 3

Newcomers· Feb 23